<DOC>
	<DOCNO>NCT02090543</DOCNO>
	<brief_summary>According recent guideline , long-term anticoagulation recommend patient atrial fibrillation ( AF ) risk profile CHA2DS2-VASc score 1 . Vitamin K antagonist ( VAK ) novel oral anticoagulant rivaroxaban current treatment option AF patient additional risk factor stroke . Currently limited information extend AF patient prefer one treatment option base patient relevant characteristic novel oral anticoagulant vs. VKAs . It also unknown characteristic influence patient preference relate neutral comparator . Furthermore , additional unknown factor also patient evaluate current treatment lead difference among treatment VKAs rivaroxaban .</brief_summary>
	<brief_title>BAY 59-7939 ( Xarelto , SPAF ) , Non Interventional Studies</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<criteria>A.General Criteria ( Group 1and Group2 ) : diagnose nonvalvular AF old 18 year general capability willingness perform structure patient interview German participation clinical observational study last 3 month Additional criterion Group1 ( VKAexperienced ) : active VKAtherapy least 3 month without significant interruption case perioperative interruption VKA treatment hold two week . Additional criterion Group2 ( rivaroxabanexperienced patient ) : active rivaroxabantherapy least 3 month without significant interruption case perioperative interruption VKA treatment hold two week . participation clinical observational study last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>